Shreyas Interm. (526335)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter net loss is negligible at around ₹0 Cr, suggesting limited near-term cash burn.
• Small market cap of ₹79 Cr means any genuine business revival could have a visible per-share impact.
• No dividend obligation currently, so management is not pressured to distribute cash while solving operations.
• As a commodity chemicals name, the asset base remains available if a viable operating plan is implemented.

Concerns

• Zero sales in the latest quarter and 0% sales growth indicate no active revenue engine.
• Negative ROE of -7.44% and ROCE of -6.34% show the company is destroying value on capital employed.
• Price-to-book of 4.54 against book value of ₹2.42 offers no margin of safety.
• Piotroski F-Score of 2/9, along with N/A debt/equity and promoter holding, raises serious financial-health and governance questions.

AI Analysis

As a value investor, my first question is not 'will the price go up?' It is 'what is this business earning on the money it employs?' Shreyas Interm. fails that test today. The company trades at ₹10.98, giving a market cap of ₹79 crore, while book value is just ₹2.42 per share. In other words, the market is asking me to pay 4.54 times net assets for a commodity-chemicals entity whose ROE is -7.44% and ROCE is -6.34%. The latest quarter shows sales of ₹0 crore and net profit of ₹0 crore—there is no operating engine. Graham warned to use a margin of safety; paying far above book value for negative earning power is the opposite. P/E is 0.00, which is not cheapness; it is absence of profit. Profit growth is -8.33%, sales growth is zero, and no dividend is being paid. The Piotroski F-Score of 2/9 is a serious red flag, pointing to weak financial health. Debt/equity is N/A, and promoter holding is N/A, so I cannot even verify who is backing this situation or how much debt sits in the capital structure. Commodity chemicals rarely gives a durable moat; without scale, pricing power, or proprietary technology, this business looks like a value trap, not a compounder. There is a wide 52-week range from ₹5.83 to ₹12.38, suggesting speculation. I would not touch this based on today's numbers. If a real turnaround emerges—genuine sales, positive returns, and improving F-score—I would revisit, but only at a price that gives me heavy protection. Until then, this is an avoid.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer